PMID- 33047769
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2047-4849 (Electronic)
IS  - 2047-4830 (Linking)
VI  - 8
IP  - 22
DP  - 2020 Nov 21
TI  - A cascade dual-targeted nanocarrier for enhanced alectinib delivery to 
      ALK-positive lung cancer.
PG  - 6404-6413
LID - 10.1039/d0bm00970a [doi]
AB  - Alectinib is a highly efficacious inhibitor for the treatment of anaplastic 
      lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in the clinic; 
      however, serious adverse events (AEs) occurred in 44.0% of patients. Herein, we 
      explored magnetic/TAT dual-targeted nanocarriers as delivery systems for 
      alectinib. Magnetic targeting efficiently enhanced the extravasation of 
      alectinib-loaded nanoparticles from vessels into the tumor tissue, while the TAT 
      targeting reactivated in the tumor tissue significantly improved the tumor 
      cellular uptake of the nanocarrier. As a result, this dual-targeted polymeric 
      nanocarrier exhibited superior therapeutic effects and induced tumor shrinkage in 
      vivo. Meanwhile, this dual-targeted nanocarrier also minimized alectinib-induced 
      hepatotoxicity, providing an efficient strategy to extend the application of 
      alectinib for NSCLC patients.
FAU - Zeng, Fanjun
AU  - Zeng F
AD  - Division of Thoracic Surgery, Guangdong Lung Cancer Institute, Guangdong 
      Provincial People's Hospital & Guangdong Academy of Medical Sciences, The Second 
      School of Clinical Medicine, Southern Medical University, Guangzhou 510080, P. R. 
      China. thoracichaiyu@gmail.com.
FAU - Xu, Bin
AU  - Xu B
FAU - Zhu, Hongyuan
AU  - Zhu H
FAU - Wu, Shaowei
AU  - Wu S
FAU - Liao, Guoqing
AU  - Liao G
FAU - Xie, Daipeng
AU  - Xie D
FAU - Huang, Luyu
AU  - Huang L
FAU - Qiao, Guibin
AU  - Qiao G
FAU - Yang, Xianzhu
AU  - Yang X
FAU - Zhou, Haiyu
AU  - Zhou H
LA  - eng
PT  - Journal Article
DEP - 20201013
PL  - England
TA  - Biomater Sci
JT  - Biomaterials science
JID - 101593571
RN  - 0 (Carbazoles)
RN  - 0 (Piperidines)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - LIJ4CT1Z3Y (alectinib)
SB  - IM
MH  - Anaplastic Lymphoma Kinase/genetics
MH  - Carbazoles
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - Humans
MH  - *Lung Neoplasms/drug therapy
MH  - Piperidines
MH  - Protein Kinase Inhibitors
EDAT- 2020/10/14 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/13 09:20
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/10/13 09:20 [entrez]
AID - 10.1039/d0bm00970a [doi]
PST - ppublish
SO  - Biomater Sci. 2020 Nov 21;8(22):6404-6413. doi: 10.1039/d0bm00970a. Epub 2020 Oct 
      13.